Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-126 · 5 trials · 4 indications
vital signs, electrocardiogram (ECG), neurological examination, laboratory tests, number of subjects with adverse events, Columbia-Suicide Severity Rating Scale (C-SSRS)
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | ABT-126 Low Dose |
| 2 | EXPERIMENTAL | ABT-126 High Dose |
| 3 | EXPERIMENTAL | Placebo for ABT-126 |
| 20mg of ABT-126 QD | ACTIVE_COMPARATOR | 20 mg of ABT-126 QD for 10 days |
| 30mg and 45mg ABT-126 QD | ACTIVE_COMPARATOR | 30 mg and 45mg of ABT-126 QD for 21 days |
| Name | Type | Description |
|---|---|---|
| ABT-126 | DRUG | Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days. |
| Placebo | DRUG | Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days. |
| Placebo for ABT-126 | DRUG | Matching Placebo for Arms 1 \& 2 |
Inclusion Criteria 1. Male or female and age between 55 and 90 years, inclusive. 2. The subject meets the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's Disease (AD). 3....
Top 20 of 23 competitors
ABT-126 is an investigational small molecule developed by Abbott Laboratories for neurological conditions. It has been studied in Phase 1 clinical trials in Alzheimer's disease, schizophrenia, and healthy volunteers. It is not approved and remains in early clinical development.
ABT-126 targets CHRNA7, the alpha-7 nicotinic acetylcholine receptor, and acts as an agonist at this target. This receptor is associated with cholinergic signaling relevant to neurological and cognitive function, which is why ABT-126 has been evaluated in Alzheimer's disease and schizophrenia.
ABT-126 is developed by Abbott Laboratories, which trades under the ticker ABT. Abbott sponsored the Phase 1 clinical studies of the compound in Alzheimer's disease, schizophrenia, and healthy volunteers.
ABT-126 is in Phase 1 clinical development. All of its recorded trials are Phase 1 studies, and none are currently active. It is an investigational agent and has not been approved for any indication.
ABT-126 has been studied in completed Phase 1 trials including NCT01482845 in Alzheimer's disease, NCT01043458 in schizophrenia, NCT00959634 in healthy volunteers, and NCT00912431, a pharmacokinetic and exploratory biomarker study in healthy volunteers. These studies enrolled a total of 50 participants across randomized, double-blind, controlled designs.
ABT-126 has been evaluated in a Phase 1 study in subjects with Alzheimer's disease, NCT01482845, which assessed safety, tolerability, and pharmacokinetics in 20 participants aged 55 and older in the United States. It is investigational and not an approved treatment for Alzheimer's disease.